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Although for many decades bisphosphonates were used for adult bone loss, bisphosphonate administration in
pediatric patients is new and was initiated in the past 15-year. The indications for pediatric bisphosphonates
was extended to childhood malignancies with bone involvement, after additional effects were unveiled for
bisphosphonates with recent research. In this article we review childhood bone loss and conditions with bone
involvement in which bisphosphonate therapy have been used. We also review mechanisms of action of
bisphosphonates, and present indications of bisphosphonate therapy in pediatric patients based on results
of clinical trials.
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The use of bisphosphonate therapy in pediatric patients
was suggested in 1998 when the cyclic administration of
intravenous pamidronate in children with osteogenesis
imperfecta resulted in reduction in bone resorption, in-
crease in bone density, and reduction in fracture inci-
dence [1]. Since the mechanism of action in children is
different from adults, as bone in children is a growing
tissue and responds to bisphosphonates differently than
the adult bone, it is difficult to extrapolate the adult bis-
phosphonate therapy regimens to the pediatric patients.
Two years after discontinuation of pamidronate therapy,
older teens with osteogenesis imperfecta maintained their
spine bone mass, while the bone mass declined in younger
teens. The persistence of gains in BMD after bisphospho-
nate therapy appeared to be dependent on the age of the
children and the amount of regional residual bone growth
[2]. In 2007 and 2014 a Cochrane Database Systemic
Review [3-5] concluded there were insufficient data to
support the use of bisphosphonates as standard therapy
in children. Importantly, although many clinical trials in
pediatric patients reported significant gains in BMD and
decrease in pain compared to placebo with bisphospho-
nates, they did not conclude that bisphosphonates signifi-
cantly reduce the incidence of fractures in osteogenesisCorrespondence: EghbaliFGuiti@aol.com
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unless otherwise stated.imperfecta [4], neither bisphosphonates improve survival
of cancer patients. However, safety and efficacy of short-
term therapy (≤2-yr) is sufficient to justify their use in se-
vere cases of bone loss such as osteogenesis imperfecta
and pediatric bone malignancies associated with fracture
and pain.Molecular mechanisms of actions of
bisphosphonates
The molecular mechanisms of action of bisphosphonates
were described recently. All bisphosphonates are charac-
terized by 2 phosphonate groups sharing a common car-
bon atom (P-C-P) backbone, responsible for the strong
affinity of bisphosphonates for bone mineral, the hydroxy-
apatite. The adsorption of bisphosphonate molecule to
bone mineral is responsible for the uptake and retention of
bisphosphonate on the skeleton, its diffusion and storage
within the bone, and its potential release from bone [6].
The simple bisphosphonates attached to calcium are taken
up by osteoclasts by endocytosis and are incorporated as
toxic, non-hydrolysable metabolites, methylene-containing
ATP analogues. Methylene-containing metabolites, or
ATP analogues, contain the P-C-P groups of bisphospho-
nates in place of the pyrophosphate (P-O-P) moiety of
ATP. ATP analogs are resistant to hydrolytic breakdown
and the release of phosphate [7]. Metabolites of simple
bisphosphonates closely resemble proton pump inhibitors
(PPi), and as such, can be incorporated into the active
site of aminoacyl-tRNA synthetase enzyme in the cell.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the cytosol of osteoclasts and cause apoptosis of these
cells. No other cell type can acidify the bone surface, a
condition required for this adsorption [8-10]. It was re-
cently found that monocytes and macrophages also were
able to internalize bisphosphonates, but only transiently.
On the contrary, RANKL and TNF alpha can prevent the
bisphosphonates apoptosis and restore osteoclast? s bone
resorption activities [9,10]. In summary, simple bispho-
sphonates act as pro-drugs, absorbed by osteoclasts where
they accumulate as toxic metabolites and cause apoptosis
of osteoclasts and prevent the bone resorption.
Nitrogen-containing bisphosphonates (N-bisphosphonates)
are up to several magnitude more potent than simple
bisphosphonates and they inhibit osteoclasts using a
different pathway [11]. N-bisphosphonates inhibit en-
zymes of cholesterol synthesis, the mevalonate enzyme
pathway and the farnesyl diphosphate synthase, within
osteoclasts. The inhibition of these enzymes prevents the
prenylation of small GTPases and causes unprenylated
GTPases. Accumulation of unprenylated GTPases modifies
important functions in osteoclasts including membrane
trafficking and ruffling, and induces apoptosis of these cells
[12]. Zoledronic acid is the most potent inhibitor of farne-
syl diphosphate synthase and has the highest affinity for
hydroxyapatite and the longest duration of action [13]. The
inhibition of bone resorption by N-bisphosphonates is not
associated with signs of cell toxicity or decrease in OC
numbers at therapeutic doses. Instead, N-bisphosphonates
can lead to the formation of ? giant? hyper-nucleated OC
associated with resorption lacunae, seen as functionally in-
active pre-apoptotic osteoclasts [14,15]. Bisphosphonates
indirectly oppose key mediators of osteoclast function and
survival, RANK/ RANKL, by increasing osteoprotegerin
(OPG) production. Increase in OPG opposes the binding
of RANKL to the RANK receptor [16-19]. In addition to
anti-osteoclastic effects, bisphosphonates have antitumor
properties. In pre-clinical trials in neuroblastoma, it is
shown that zoledronic acid stimulates tumor-specific T
cells by enhancing the anti-tumor activity of natural-killer
cells [20]. In clinical trials, zoledronic acid combined with
conventional chemotherapy, decreases the production
of IL6, which is associated with poor-outcome of neu-
roblastomas [21]. Despite a decrease in bone remodeling,
bone formation parameters are maintained because osteo-
blasts remain active, resulting in a positive remodeling
balance [22].
Effects of bisphosphonates on pediatric patients
In children with osteogenesis imperfecta, the most studied
cause of pediatric bone loss, intravenous pamidronate
therapy increases the size of vertebral bones and reshapes
pre-existing vertebral compression fractures. Older chil-
dren with lower bone density gains more in BMD thanyounger, although younger children have less deficit in
BMD at base [23]. Two years after discontinuation of
intravenous pamidronate, areal BMC Z-scores in osteogen-
esis imperfecta children remains above pretreatment levels
but below normal levels [24]. Trans-iliac histophotometry
after 2 years intravenous pamidronate therapy shows max-
imal increases in cortical and cancellous bone thicknesses,
with considerable increases in trabecular number [25]. The
cortical width of iliac bone almost doubles during the first
2 years of pamidronate therapy, but changes little when
therapy is continued for another 2-year. These results sug-
gest stored bisphosphonates maintain their biological activ-
ity at least 2 years after discontinuation.
Although in adults, bisphosphonates appear to suppress
bone resorption up to 10 years after discontinuation, in
younger children because of higher bone turnover, recovery
of recycled bisphosphonates from bone is shorter. Children
with osteogenesis imperfecta treated with bisphosphonates
at early age have normal or improved growth and new bone
acquisition is reported in studies on long bone fractures
after discontinuation of pamidronate therapy. Bisphospho-
nates at usual therapeutic doses do not permanently appar-
ently disable the bone turnover mechanisms, neither usual
therapeutic doses result in osteopetrosis. Overall, pamidro-
nate therapy decreases bone remodeling, however bone
formation parameters are less inhibited than bone re-
sorption parameters, resulting in a positive remodeling
balance [22]. Urinary NTX excretion decreases signifi-
cantly with bisphosphonates and increases slightly after
discontinuation above normal healthy levels, but it re-
mains well below pretreatment levels [23]. Neither radio-
logical changes in bone density nor urinary NTX are
correlated with changes in BMD [25].
The improvement of BMD with only one infusion of zo-
ledronic acid every 6 months for 1 year, and 3 monthly in-
fusion for 12 months, were similar in pediatric spinal cord
injury [26]. Also, one single infusion of zoledronic acid in
adult patients reduces >30% the rate of clinical fractures
over 3 years of follow up, compared with placebo [27].
These important observations, points to the possibility of
shorter safer length of therapy, longer dose interval with
sustained effects, and a better acceptance by patients.
The safe upper limit dose for each entity of bisphospho-
nate is not yet established [3]. A 2014 Cochrane Systemic
Review assessed the effectiveness and safety of bis-
phosphonate therapy. Effect on fracture reduction was
inconsistent and was observed in only two trials with sta-
tistically significant difference between oral or intravenous
bisphosphonates compared to placebo control. All trials
reported statistically significant increase in lumbar spine
BMD Z-scores. The outcome between zoledronic acid and
intravenous pamidronate were not different. Neither oral
nor intravenous bisphosphonates improved significantly
bone pain, growth, and functional activity versus placebo.
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and small number of pediatric patients the Systemic
Review did not confirm that bisphosphonates decrease
consistently fracture rate, nor they consistently improve
pain or the functional mobility [5].
Adverse effects of bisphosphonates in pediatric patients
Bisphosphonates are generally well tolerated in pediatric pa-
tients. Adverse effects are limited, and are predictable based
on previous trials. In most cases ? acute phase reaction? is
observed with fever, malaise, abdominal pain, vomiting,
muscle or bone pain with the initiation of either intravenous
or oral agents within 1? 3 days, and lasting few days [1,28].
Asymptomatic hypophosphatemia, and hypomagnesaemia
and hypocalcemia causing tetany are rare and prevented
with supplementation with calcium and vitamin D [29].
More serious side effects seen in adults including uve-
itis, thrombocytopenia, esophageal or oral ulcerations, are
rare in children. One case of uveitis was reported among
19 children with Langerhans cell histiocytosis treated with
bisphosphonates in a retrospective study in Japan [30].
Avascular necrosis of the jaw seen in adult [31] is not seen
in pediatric patients. Severe case of respiratory distress
syndrome was reported with initiation of pamidronate in
an infant with history of airway disorders [32]. Osteomal-
acia was seen in an adolescent with fibrous dysplasia after
intravenous cyclic pamidronate therapy [22].
Long term retention of high-affinity bisphosphonates is
the major concern in young girls [33-35]. In experimental
studies, bisphosphonates readily crossed the placenta. Thus
bisphosphonates can possibly affect fetuses and cause hypo-
calcemia. Skeletal anomalies in offspring is seen in animal
models [36]. A pregnancy test is recommended before ther-
apy in teenage young women. However, full extent of fetal
risks is still unknown in humans because of small number of
fetuses exposed. In two infants delivered to mothers treated
with bisphosphonates, asymptomatic hypocalcemia without
any skeletal anomaly was reported in the newborn [35].
The greatest concern in the young patients is long term
suppression of bone turnover. Osteopetrosis and patho-
logical fractures were developed in a 12 year child treated
for idiopathic hyperphosphatemia, treated with high doses
of pamidronate for 33 months (up to 100 mg intravenously
every three weeks) [37]. Transient and dose-dependent in-
hibitory effects on bone length and growth were also ob-
served in mice after zoledronic acid therapy [38]. In a
phase I trial of zoledronic acid combined with cyclophos-
phamide in neuroblastomas, two cases of osteosclerosis
out of 21 children were reported [21].
Pediatric bone disorders: candidates for bisphosphonate
therapy
The major indication for bisphosphonates in pediatric
patients is osteoporosis either primary or secondary.Additional antitumor properties of bisphosphonates have
recently added a second indication for bisphosphonates as
adjuvant medication with chemotherapy in pediatric bone
malignances.
Definition of childhood osteoporosis: Fractures with
minor trauma in apparently healthy children might be a
complication of unrecognized disorders with bone loss
[39]. One out of 3 otherwise healthy children fractures by
age 17 [40-42]. The 2013 revised position of International
Society for Clinical Densitometry (ISCD) defines osteopor-
osis in children by two criteria 1) the presence of a signifi-
cant fracture history indicated by either one or more
vertebral compression (crush) fractures in the absence of
local disease or trauma or, two or more long-bone fractures
by age 10 or, three or more long-bone fractures at any age
up to age 19; and 2) a low bone mineral content and areal
bone mineral density (aBMD) with BMC/BMD Z-score ≤
? 2.0 SD [43] [http://www.iscd.org] 2013 Pediatric Official
Positions]. However aBMD Z-score ≥ ? 2.0 SD does not ex-
clude osteoporosis in high risk patients since long bone
or vertebral compression fractures might occur with low
impact trauma. The posterior-anterior (PA) spine densi-
tometry and a ? total body less head? (TBLH) are the pre-
ferred skeletal sites for BMC and aBMD measurements.
ISCD has recommended that the time interval between 2
DXA be not less than 6 months.
Primary pediatric osteoporosis result from intrinsic
skeleton abnormalities, such as heritable disorders. The
most common cause of primary pediatric osteoporosis is
osteogenesis imperfecta, an inherited disorder character-
ized with bone fragility and low bone mass with an inci-
dence of 1/10,000 births, caused by mutations of two
genes that encode collagen type I alpha chain, COL1A1
and COL1A2 genes [44]. There is a wide variety of clinical
severity and phonotypes, associated with a wider variety
in genetic characteristics [45]. The four initial clinical
types of osteogenesis imperfecta as described by Sillence
[46,47] are type I with no bone deformity, type II le-
thal in perinatal period, type III the most severe form
in children surviving the neonatal period, with ex-
tremely short stature and short limbs, multiple spinal
fractures and secondary deformities, and type IV with
less severe bone deformities and variable short stature.
Three additional types were later described with the
same phenotypes as the first four types but with mu-
tations not related to collagen genes and are types V,
VI, and VII [48-51].
Bruck Syndrome and Ehlers-Danlos syndrome are rare
heterogeneous autosomal recessive disorders phenotyp-
ically similar to osteogenesis imperfecta characterized by
bone fragility. The genetic mechanism however consists
of posttranslational modifications of collagen COL3A1
gene that result in an aberrant cross-linking of bone col-
lagen due to under-hydroxylation [52-55].
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order, results from mutations in the FBN1 gene, which en-
codes fibrillin-1, an extracellular matrix component found
in micro-fibril structures characterized by wide variety of
skeletal, ocular, and cardiovascular anomalies [56,57].
Osteoporosis-pseudoglioma syndrome is a recessive auto-
somal genetic disorder involved with primary severe child-
hood osteoporosis and visual disturbances. Mutations
in the low-density lipoprotein receptor-related protein
5 gene (LRP5) have been frequently detected [58].
Secondary childhood osteoporosis result from divers
processes outside of the skeleton. They comprise neuro-
muscular disorders associated with immobilization such
as cerebral palsy, Duchenne muscular dystrophy (DMD),
and spinal cord injury. DMD is an X-linked disorder aris-
ing from mutations in the dystrophin gene, which encodes
a structural muscle fiber protein. In DMD association of
severe muscle weakness, impaired motility, might result in
high incidence of vertebral compression fractures some-
time aggravated with corticoid therapy [59,60].
Chronic illnesses such as eating disorders, liver failure,
and coeliac disease, chronic inflammatory conditions in-
cluding inflammatory bowel disease, systemic lupus ery-
thematosus, HIV, renal failure, and severe burns also
cause bone loss.
Secondary amenorrhea are also associated with second-
ary osteoporosis and include functional hypothalamic
amenorrhea characterized by the dysfunction of the
hypothalamic-pituitary-ovarian axis, absence of functional
or anatomical lesion, associated often with stress, weight
loss, or excessive exercise [61,62]. In this syndrome, sup-
pression of gonadotropin-releasing factor (GnRF) pulsati-
lity, over-activity of hypothalamic-pituitary-adrenal axis,
increased secretion of corticotropin-releasing hormone,
disturbance of the hypothalamic-pituitary-thyroid axis
[63], and estrogen deficiency [62] are present. The ? female
athlete triad? refers to amenorrhea, osteoporosis, and poor
nutritional behavior, seen in exercise-induced amenorrhea
[64,65]. Eating disorders are 10 times more common in fe-
males and result in secondary amenorrhea in girls and low
testosterone in boys. Osteopenia, osteoporosis, shorter
stature, and high rates of stress fracture characterize an-
orexia nervosa [66,67]. Other endocrine and reproductive
disorders with hypogonadism and secondary osteoporosis
include Turner syndrome, growth hormone deficiency,
hyperthyroidism, diabetes, hyper-prolactinemia, and glu-
cocorticoids excess (Cushing syndrome). Causes of iatro-
genic osteoporosis include osteoporosis associated with
glucocorticoid [68,69], methotrexate, cyclosporine, radio-
therapy, GnRH agonists, T4 suppressive therapy and fi-
nally, anticonvulsants therapy. Thalassemia, a hereditary
anemia resulting from defects in hemoglobin synthesis, is
among the most common genetic disorders with a world-
wide incidence of 4.4 per 10,000 birth [70,71]. Theincidence of osteopenia or osteoporosis is estimated from
60 to 90% starting in early age, with significant decrease
in OPG/RANKL ratio [72] and imbalance between bone
formation and bone resorption [73,74]. Inborn errors of
metabolism associated with bone loss and osteoporosis
include glycogen storage diseases, galactosemia, Gaucher
disease, and homocystinuria.
Langerhans cell histiocytosis is a chronic proliferative
disease characterized by uncontrolled clonal proliferation
of CD1a + dendritic Langerhans cells, mostly proliferating
in bone tissue [30].
Pediatric malignancies with bone involvement result
in significant pain and increased morbidity and mortality
[75]. The key mediator of osteoclasts survival, RANKL
[16-19] is secreted by both osteoclasts and by malignant
cells and promotes the bone resorption [76].
Neuroblastoma, the most frequent extra-cranial tumor
in children has a bone metastasis rate of 56% that is gen-
erally present at diagnosis, increasing the morbidity and
mortality [19]. High peripheral blood level of IL6 is asso-
ciated with poor-outcome of neuroblastoma, and is be-
lieved to stimulate the invasion of osteoblastoma tumor
cells to bone microenvironment. IL6 levels decrease with
zoledronic acid combined with cyclophosphamide in
pediatric patients with neuroblastoma [20,21].
Ewing ? s sarcoma, the second most frequent bone ma-
lignancy behind osteosarcoma in pediatric and adoles-
cent patients, in 85% of cases, is defined by a chromosomal
translocation of t(11;22)(q24;q12) [17]. Osteosarcoma, if
localized at diagnostic, and when treated, has a 5-year
overall survival rate of 70%, that drops to < 15% in patients
with multifocal disease or relapse [17].
Initial and supportive therapy of pediatric bone
disorders
Management of the primary disorders generally improves
childhood osteoporosis. Weight control in eating disorders,
early management of amenorrhea in anorexia nervosa [67],
physical therapy in children with restricted mobility [77],
correction of hemoglobin levels by transfusion and preven-
tion of iron overload in thalassemia with iron chelating
[71,78], are the initial steps. Adequate daily intake of cal-
cium and vitamin D are necessary. In osteogenesis imper-
fecta, lower serum 25OH-D levels are associated with both
lower LS-aBMD Z-scores and with higher urinary bone
turnover indexes (urinary NTX/Cr). Every 1 nmol/liter
increase in 25OH-D increases the Z-score by 0.008. The
current conservative consensus is to maintain serum
25OH-D levels above 50 nmol/liter (20 ng/ml) [79].
The 25OH-D levels are also inversely associated with
PTH concentrations [80]. Recombinant hPTH therapy,
the most effective anabolic agent in management of adult
osteoporosis, has caused osteosarcomas in growing animal
models and its use in children is not acceptable [81].
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protegerin (OPG) [83] or stimulation of production of
OPG that decreases RANKL/OPG ratio [16-18], has been
considered in metastatic bone cancers. The administration
of sex steroids in anorexia nervosa does not increase the
BMD in adults [84] and it is not recommended in children.
Selected pediatric conditions treated with
bisphosphonates
We have summarized major recent clinical trials, which
studied bisphosphonate therapy in pediatric patients, in
Table 1. Major pediatric conditions treated with bispho-
sphonates are discussed below:
Osteogenesis imperfecta
In an uncontrolled observational study in children with
severe osteogenesis imperfecta, intravenous pamidronate
6.8 ? 1.1 mg/kg/year was administered up to 5 years.
There was a mean annual increase in BMD of 42 ? 29%,
with increase in Z-score increment of about 2 points.
There was also improvement of mobility, and the fracture
rate decreased compared to the rate before therapy [1].
A clinical trial analyzed bone densitometry of boys
and girls aged 2 weeks to 17 with osteogenesis imper-
fecta types I, III, and IV, who received a 4-year intraven-
ous pamidronate compared to ? untreated ? age- and
type-matched controls. Patients with ages < 2 years re-
ceived 0.25 mg/kg day 1, and 0.5 mg/kg days 2 and 3
every 8 weeks. Ages 2 ? 3 years received 0.38 and
0.75 mg/kg day 1 and days 2 ? 3 respectively, every
12 weeks. Those ages >3 years received 0.5 and 1 mg/
kg/day, day1 and days 2? 3 respectively, every 16 weeks.
Total yearly doses in the 3 groups were the same. Results
concluded that spine aBMD Z-scores, BMC, bone volume,
and volumetric BMD significantly increased with intraven-
ous pamidronate compared to control untreated children
(p < 0.001 for each). The treatment was associated with
both increased cortical thickness and increased trabecular
compartment evidenced by both radiological and histo-
photometric analyses. Results suggested the most severely
affected patients at the baseline were the older children
and they were the ones who benefited more from intra-
venous pamidronate therapy [23]. Changes in serum alka-
line phosphatase and urinary NTX did not correlate with
gains in bone mineral density. The type of collagen muta-
tions had no influence on results of the study [22]. Also
transiliac histophotometry indicated that cancellous bone
volume and cortical width initially increased signifi-
cantly but changed little after year 2 of therapy [25]. To
compare the effectiveness of intravenous versus oral bis-
phosphonate therapy, a 2-year oral alendronate therapy
was also used in prospective, randomized, double-blind
placebo-controlled, multicenter trials in boys and girls
aged between 4 and 18 with osteogenesis imperfecta. Oralalendronate was given at 5 mg/d and 10 mg/d doses in
children < 40 kg and >40 kg respectively, for 2 years. Oral
alendronate significantly increased lumbar spine BMD
Z-scores mostly in the first year, and suppressed sharply
urinary bone resorption index, the urinary NTX the first
6 months then changed little the remaining time com-
pared to control (p < 0.001 for each). The incidence of
long-bone fractures, the average vertebral heights, the cor-
tical thickness, bone pain and finally functional activity
were similar to the control placebo group [28]. Taken to-
gether the study concluded that the fracture outcome,
bone pain, and quality of life were improved with oral
alendronate and were comparable to intravenous bispho-
sphonates at doses used [28].
A controlled trial treated severely affected osteogenesis
imperfecta children under 3 years of age for a period of
12 months with intravenous pamidronate in 3 consecutive
days for four to eight cycles, with an average cumulative
dose of 12.4 mg/kg. The age-matched, severity-matched
controls did not receive the treatment. BMD in treated
children increased dramatically up to 227% (p < 0.001),
and fracture rate decreased significantly (p < 0.01) com-
pared to untreated control children [85]. Side effects were
minor and as expected. This trial confirmed the intraven-
ous pamidronate in very young and severely affected
osteogenesis imperfecta children is safe and beneficial.
Intravenous pamidronate 10 mg/m2 per day administered
for 1 year to types III and IV osteogenesis imperfecta chil-
dren in a randomized controlled trial, increased significantly
lumbar spine BMD Z-scores and volumetric vertebral size.
Fracture rates decreased in upper extremities and not in the
lower extremities, functional mobility and pain were not im-
proved, and a second year extension of the therapy did not
additionally significantly improve the bone density [86].
In a retrospective case? control study in children and ad-
olescents with low BMD, who had no osteogenesis imper-
fecta and no metabolic bone disease, cumulative dose of
oral alendronate was compared with DXA changes. The
results indicated that alendronate does not improve bone
density in children with primarily neuromuscular disease
and without osteogenesis imperfecta compared to control
patients with no treatment at all [87].
In a randomized placebo-controlled, multicenter trial,
daily risedronate 2.5 or 5 mg for 1 year, in children 4 ? 15
years with osteogenesis imperfecta, increased signifi-
cantly lumbar spine BMD compared to control (p <
0.0001). The rate of clinical fractures decreased signifi-
cantly as well after 1 year of therapy (p = 0.045). But in
the follow up in years 2 and 3, the rate of clinical frac-
tures did not change significantly in patients treated with
risedronate compared to placebo-treated controls [88].
Results of these studies, and also safety issues, suggest
that bisphosphonate therapy should be discontinue after
1 ? 2 years of therapy.
Table 1 Selected trials with bisphosphonate and doses used, p value of spine BMD and fracture reduction rates, compared to control
Year Author Disease Age Trial type Duration of therapy Bisphosphonate Doses Spine BMD vs CTL Fr Reduction vs CTL
1998 Glorieux FH OI range 4 - 15 Uncontrolled, 5 year IV PAM 6.8 ? 1 mg/kg/year p < 0.001 p < 0.001
Observational
2000 Plotkin H OI < 3 Controlled 1 year IV PAM 12.5 mg/kg/year p < 0.001 p < 0.01
2005 Letocha AD OI range 4 - 13 Randomized, 1 year IV PAM 1 mg/kg/d ? 3d/3 M p = 0.054 p = 0.04
Controlled
Observational 2 years
2005 Golden H Aneroxia N range 15 - 19 Randomized 1 year Oral ALN 10 mg/d p = 0.02
Double-Blind,
Placebo-controlled
2005 Rudge, S Corticoid-in. range 4 - 17 Randomized 1 year Oral ALN 1-2 mg/kg/week p = 0.013
osteoporosis Double-Blind,
Placebo-controlled
2010 Bachrach SJ C P mean 11 Controlled 13 months IV PAM unspecified p = 0.02
Observational mean 4 years
2011 August KJ Cancer relapse mean 12.5 y Retrospective 3 years IV ZOL >10 y 4 mg no Statistics
range 1? 23 y <10 y 0.08-0.16 mg/kg
2011 Ward LM OI range 4 - 19 Randomized 2 years Oral ALN <40 kg 5 mg/day p < 0.001 p = 0.07
Double-Blind, >40 kg 10 mg/day
Placebo-controlled
2011 Russel HV Neuroblastoma mean 7.5 y Observational capped at 4 mg IV ZOL 2 mg/m2 Prolonged stability
reccurent range 0.8 - 25 Dose limiting toxicity Escalating doses/28-d 3 mg/m2 no Statistics
NANT (+ Cyclophos) 3-4 mg/m2
2013 Bishop N OI 4 - 15 Randomized 1 year Oral Risedronate 2.5 mg/d or 5 mg/d p < 0.0001 p = 0.044
Multicenter Observational years 2-3
Double-Blind,
Placebo-controlled
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Glucocorticoid-associated osteoporosis in growing chil-
dren is associated with a 20% increase in age-adjusted
fracture rates [68,69]. Glucocorticoids inhibit bone forma-
tion by decreasing the number of osteoblasts and increas-
ing the rate of bone resorption by stimulating osteoclasts.
Glucocorticoids decrease intestinal absorption and increase
the renal excretion of Ca. In adults, a daily dose less than
7.5 mg glucocorticoids have been linked to such changes.
In adults, alendronate effectively prevents glucocorticoid-
induced osteoporosis [7,89]. Data from uncontrolled
studies, in children receiving glucocorticoids treated
with bisphosphonates have demonstrated significant
increases in spinal bone density Z-scores after intra-
venous bisphosphonates or oral alendronate [90]. In a
small placebo-controlled study in children with chronic
illnesses treated with glucocorticoids, oral alendronate
1-2 mg/kg body weight/week for one year was well toler-
ated and increased bone density and volumetric size of the
lumbar spine, and decreased indexes of bone resorption
but did not improve bone growth and the size of long
bones [91]. Severe corticoid-induced bone loss in Duchenne
muscular dystrophy was reduced with bisphosphonate ther-
apy [59,60].
Pediatric bone malignancies
Pamidronate and zoledronic acid are the most rigorously
studied N-bisphosphonates in adult malignancies, in
addition to reducing pain and reducing fracture inci-
dence in bone metastatic cancers, they have also an anti-
tumor activity. In preclinical trials in pediatric cancers,
Zoledronic acid was used as an active anticancer agent,
with low incidence or no significant side effects in neuro-
blastoma [19,20], osteosarcoma [92], and in Ewing ? s sar-
coma [93,94].
In a phase I clinical trial in children with recurrent/
refractory neuroblastoma, zoledronic acid combined with
cyclophosphamide resulted in prolonged disease stability
in about 50% of cases. The maximum tolerated dose of
4 mg/m2/every 28 days was recommended since it was
more effective than 2 mg/m2 dose. Most side-effects were
transient and tolerable. However one case of osteosclero-
sis complicated by fracture was reported in this study [21].
In retrospective studies [75], pediatric patients with skel-
etal metastatic malignancies were treated at least with one
dose of intravenous zoledronic acid in combination with
chemotherapeutic regiments. Patients above 10 years age
received the recommended adult dose of 4 mg/kg and
those younger than 10 received between 0.08 ? 0.16 mg/
kg. Results of these studies confirmed that zoledronic acid
alleviates pain in metastatic bone cancers, has the potential
antitumor actions, and has low incidence of side effects.
In Ewing sarcomas, experimental and preclinical trials
have indicated the benefit of bisphosphonates as adjuvanttherapies [95]. In vitro, zoledronic acid significantly in-
hibits Ewing sarcoma [94] and osteosarcoma [92] cell lines
invasiveness and cell cycles [93]. In mouse models, zole-
dronic acid inhibits the tumor development of Ewing sar-
coma in bone and reduces the dissemination of lung
metastasis. However zoledronic acid neither opposes the
growth of already established metastasis, nor opposes the
progression of the tumor in soft tissues in Ewing sarcoma
models [94].
In preclinical animal models and in vitro studies of
neuroblastoma, zoledronic acid stimulates natural killer T
cells, thus inhibiting the growth of neuroblatoma tumor
cells [20], and in combination with chemotherapeutic
agents, both prevents and reduces bone metastasis [19]. A
phase I study for new approaches in therapy of neuro-
blastoma (NANT) has concluded that 4 mg/m2/28 days
zoledronic acid combined with cyclophosphamide will re-
sult in stability of most cases of neuroblastomas [21].
In retrospective studies on osteonecrosis in children
related to chemotherapy, 1 year pamidronate [96] or on
osteonecrosis unrelated to chemotherapy, one year zole-
dronic acid [97], improved pain, BMD, and motor func-
tion and opposed joint destruction.
Side-effects reported in pediatric bone malignancy are
those already expected. These include initial phase reac-
tion [29,32,33], transient hypophosphatemia and hypo-
calcemia, prevented with supplementation with calcium
and vitamin D [21,75].
Because of long half-life of zoledronic acid and second-
ary release of compounds, and possible inhibition of
growth of long bones, long term safety is the major con-
cern. Overall the improvement of the survival in pediatric
cancer patients has yet to be determined and further study
is needed. A French multicenter randomized phase III trial
(OS2006- NTC00470223) is currently under way that
might lead to establish appropriate pediatric dosages in
bone malignancy.
Secondary amenorrhea in young girls
Anorexia Nervosa is associated in nearly 50% with severe
bone loss, preferentially in the spine [84]. There is a
relative hypogonadism, low IGF-1, relative hypercortiso-
lemia, low leptin, and increase adiponectin. Limited data
for anorexia nervosa [34] indicates that bisphosphonate
treatment reduces bone turnover and increases bone
density. Risedronate 35 mg/week for 12 months admin-
istered to adult female with anorexia nervosa, has im-
proved significantly bone densities of spine and femoral
neck [84]. Oral alendronate 10 mg daily in randomized
placebo-controlled trial, has also increased significantly
the femoral neck and lumbar spine BMD from baseline
in adolescents with anorexia nervosa vs placebo-treated
patients [98]. Estrogen/progestin therapy is ineffective in
preventing or reversing bone loss in girls with anorexia
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does not increase BMD to normal levels and it still an
experimental strategy [100-102]. Testosterone therapy in
adults female does not improve bone density [34,84] and
should not be administered in young girls with anorexia
nervosa. Weight gain in anorexia nervosa and exercise
reduction in athletic girls typically leads to the restor-
ation of menses [62,64].
Overall there are limited data supporting improve-
ment of bone loss by bisphosphonate therapy in sec-
ondary amenorrhea in adolescent girls. Thus, because
of unknown teratogenic effects on the fetus, bisphospho-
nates use in adolescent girls with secondary amenorrhea is
questionable [34,62,98].
Histiocytosis
In Langerhans cell histiocytosis, a retrospective study con-
ducted in Japanese children aged 2.3? 15.0 years, pami-
dronate administered intravenously at a median dose of
1.0 mg/kg/day for 3 days per cycle, between six to ten cy-
cles at 4 to 8-week intervals, appeared to resolve the le-
sions in bone, skin, and soft tissues. In this study, one case
of acute phase reaction, one case of uveitis, and two cases
of hypocalcemia were reported in 16 children treated with
pamidronate [30].
McCune-albright syndrome, fibrous dysplasia
Fibrous dysplasia is a rare disorder arising from GNAS mu-
tations that results in bone marrow cell proliferation and in
fibro-osseous tissues in bone and bone marrow. Limited
studies have demonstrated benefits of pamidronate improv-
ing pain and markers of bone turnover [103,104].
Bone losses in impaired mobility
Cerebral palsy is characterized by impaired movements and
posture, arising from abnormalities in the central motor
neurons, and resulting in high prevalence of osteoporosis in
children. Data from multiple controlled trials and meta-
analysis studies in children with cerebral palsy treated with
pamidronate or risedronate, concluded the treatment im-
proved the BMD and reduced significantly the fracture
rate after 1 year therapy [105,106], while in some trials the
protective effects lasted beyond 4 years after the end of
the 1-year therapy [107].
In Duchenne muscular dystrophy, other condition with
impaired mobility, a retrospective analysis of patients with
vertebral compression fractures treated with pamidronate
or zoledronic acid demonstrated improvement in pain,
and in BMD in vertebra. Prolonged glucocorticoid therapy
in DMD combined with severe muscle weakness and im-
paired motility resulted in severe bone loss and vertebral
compression fractures that was treated with bisphospho-
nate therapy [59,60].Spinal cord injuries are characterized by prolonged
immobilization and muscle atrophy and result in rapid
bone loss and high incidence of long bone fractures. Lim-
ited case reports have shown improvement of BMD with
the use of bisphosphonates in spinal cord injury in adults
and children [26,108].
Bisphosphonates in in young girls with thalassemia, be-
cause of possibility of future pregnancy, should be care-
fully considered [71,78,109].
Conclusion
In summary simple non-nitrogen-containing bisphospho-
nates result in accumulations of toxic products that lead to
osteoclastic cell death while nitrogen-containing bispho-
sphonates inhibit osteoclast functions and activity. Both
types of bisphosphonates reduce bone turnover, while the
rate of bone resorption is more reduced than the rate of
bone formation. The degree of avidity for the bone tissue
of particular bisphosphonate determines the duration of
action of the bisphosphonate after discontinuation. While
long-acting bisphosphonate are a better choice for adults,
they might be an undesired choice for children with grow-
ing bone. Because of possible unknown teratogenic effects,
the long half-life make the bisphosphonate a questionable
medication for young girls. There is not sufficient long-
term efficacy and safety data for bisphosphonate therapy
in pediatric age group. However short-term use appears
to improve bone density and pain in conditions such
as osteogenesis imperfecta, chronic corticoid therapy,
and bone malignancy.
The 2014 Cochrane Database Systemic Review confirmed
the positive effects of bisphosphonates concluding that
bisphosphonates increase bone density in children and ado-
lescents with osteogenesis imperfecta. There is not enough
data to conclude whether bisphosphonates improve clinical
status by improving growth and functional mobility in
osteogenesis imperfecta. However intravenous bisphospho-
nates are associated with improved fracture rate in extrem-
ities and heights of vertebras.
Rational behind the use of bisphosphonates in bone
malignancies is based on selective accumulation in bone
tissue, potent inhibition of bone resorption by inducing
osteoclasts apoptosis and increasing osteoprotegerin
(OPG) production, and antitumor effects of bisphospho-
nates. In pediatric cancers with bone involvement, the
improvement of pain, the slowdown in metastatic progres-
sion, and stabilization of the primary disease by bispho-
sphonates, make these medications desirable. Multicenter
randomized phase III trials for pediatric bone malignan-
cies (French OS2006- NTC00470223) might lead to
establishment of appropriate dosages, optimal methods
and duration of therapy, and to determination of long
term safety of bisphosphonate therapy in overall pediatric
patients.
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ture randomized studies of bisphosphonate therapy in
pediatric age group to propose better evidence based
recommendations.
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